CNTO 148

CNTO 148 구조식 이미지
카스 번호:
476181-74-5
상품명:
CNTO 148
동의어(영문):
Simponi;CNTO 148;Golimumab;Research Grade Golimumab;Research Grade Golimumab (DHB94404)
CBNumber:
CB32657887
분자식:
포뮬러 무게:
0
MOL 파일:
Mol file

CNTO 148 속성

저장 조건
Store at -20°C
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
유해 물질 데이터 476181-74-5(Hazardous Substances Data)
그림문자(GHS): GHS hazard pictograms
신호 어: Danger
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H334 흡입 시 알레르기성 반응, 천식 또는 호흡 곤란 등을 일으킬 수 있음 호흡기 과민성 물질 구분 1 위험 GHS hazard pictograms P261, P285, P304+P341, P342+P311,P501
예방조치문구:
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P285 환기가 잘 되지 않는 곳에서는 호흡기 보호구를 착용하시오
P304+P341 들이마신 경우,호흡이 어려운 경우 환자를 신선한 공기가 있는 곳으로 옮기고 호흡하기 편한 자세로 안정을 취하게 함
P342+P311 호흡기 증상이 나타나면 의료기관(의사)의 진찰을 받으시오.
P501 ...에 내용물 / 용기를 폐기 하시오.

CNTO 148 C화학적 특성, 용도, 생산

개요

The proinflammatory cytokine tumor necrosis factor-alpha (TNF-α) has been implicated as the primary mediator of articular inflammation in diseases such as RA, PsA, and AS. Targeting TNF-a has been a successful strategy in the intervention of a range of immunoinflammatory disorders. Biologics have risen to the forefront of TNF-α blockade with infliximab, a chimeric monoclonal antibody (mAb), and etanercept, a fusion protein comprised of the ligand-binding segment of the soluble TNF receptor, reaching the market in the late 1990s for the initial indication of RA. Since then, their use has expanded to other diseases of inflammatory etiology, and two additional TNF-α inhibitors have joined the competition. Golimumab, a human anti-TNF-α mAb that binds to both soluble and transmembrane forms of TNF-a, is the first once-monthly subcutaneous agent to enter the market and is currently approved for the treatment of RA in combination with methotrexate (MTX), PsA alone or in combination with MTX, and AS. .

용도

Treatment of allergic asthma.

부작용

The most common adverse reactions, occurring with an incidence >5%, were upper respiratory tract infection and nasopharyngitis. Regarding drug interactions, live vaccines should not be administered while being treated with golimumab. As an increased risk of serious infection has been associated with concomitant use of abatacept and anakinra, combination of these drugs is not recommended. Also, golimumab treatment should not be initiated in patients with an active infection. Furthermore, patients should be warned about the higher incidence of malignancies observed with anti-TNF-a therapy and increased risks of worsening or new onset of heart failure, of exacerbation or new onset of demyelinating disease, and of hepatitis B reactivation.

CNTO 148 준비 용품 및 원자재

원자재

준비 용품


CNTO 148 공급 업체

글로벌( 13)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Shanghai EFE Biological Technology Co., Ltd. 021-65675885 18964387627
info@efebio.com China 9709 58
ShangHai Biochempartner Co.,Ltd 17754423994 17754423994
2853530910@QQ.com China 8011 62
Alchemist-pharm chemical Technology Co. Ltd. 0371-67991738 13783628208
carl@alchemist-pharm.com China 1877 58
Wuhan Chemstan Biotechnology Co., Ltd. 15926423062
422450190@qq.com China 10132 58
Hubei Kele Fine Chemical Co., Ltd 027-59101668 19945030958
2881924765@qq.com China 7980 58
Shaanxi DIDU pharmaceutical and Chemical Co., Ltd 17691182729 18161915376
1046@dideu.com China 10008 58
Wuhan Yingnuo Pharmaceutical Technology Co., Ltd. +86-027-59232304 15387063101
2881924050@qq.com China 9991 58
AntibodySystem 027-65279366 18162686757
biolab-reagents@atagenix.com China 9790 58
Wuhan Jingkangen Biomedical Technology Co., Ltd 13720134139 13720134139
orders@jknbiochem.com China 4955 58
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd 021-59167510 18117107507
vip@med-life.cn China 5019 58

CNTO 148 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved